Alterity Secures U.S. Patent Protection for ATH434 Through 2045

Key Points

• Alterity Therapeutics received a new U.S. composition-of-matter patent covering a crystalline mesylate form of ATH434, its lead treatment candidate for multiple system atrophy.
• The patent is expected to provide ATH434 protection through at least 2045 and may be eligible for Orange Book listing following potential FDA approval.
• Alterity plans to begin Phase 3 trial activities for ATH434 in multiple system atrophy by the end of 2026.
• ATH434 has FDA Fast Track and Orphan Drug designations, but it remains investigational and has not been approved for marketing.

Alterity Therapeutics (NASDA: ATHE) has received a new U.S. composition-of-matter patent for ATH434, strengthening intellectual-property protection for its lead treatment candidate for multiple system atrophy, or MSA. The patent covers a crystalline mesylate form of ATH434 and is expected to provide protection through at least 2045.

New U.S. Patent Strengthens ATH434’s Long-Term Commercial Potential

The newly granted patent, titled “Crystalline Form, and Process for its Production,” covers a specific crystalline mesylate form of ATH434 as well as methods for using it to treat neurological conditions. Alterity said this formulation was used in its Phase 2 MSA clinical studies and is expected to be used in the company’s planned Phase 3 trial.

The patent further expands Alterity’s intellectual-property portfolio and could provide a longer period of market protection if ATH434 is ultimately approved. The company expects the patent to be eligible for Orange Book listing following potential FDA approval.

ATH434 Is Being Developed for Multiple System Atrophy

ATH434 is an investigational oral therapy designed to reduce excess iron accumulation in the brain and address abnormal protein aggregation linked to neurodegenerative disease. Alterity’s primary focus is MSA, a rare, progressive Parkinsonian disorder that affects movement, balance, blood-pressure regulation, and other autonomic functions.

Alterity Prepares for a Phase 3 MSA Study in 2026

Alterity plans to begin Phase 3 trial activities for ATH434 in MSA by the end of 2026. The program follows reported Phase 2 data that included clinical findings, biomarker evidence of target engagement, and a favorable safety profile.

Phase 3 testing will be important in determining whether ATH434 can demonstrate a clinically meaningful benefit and an acceptable safety profile in a larger patient population.